Review
Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development

https://doi.org/10.2133/dmpk.DMPK-10-RV-062Get rights and content

Summary:

Toxicity has been estimated to be responsible for the attrition of approximately one-third of drug candidates and is a major contributor to the high cost of drug development, particularly when not recognized until late in clinical trials or post-marketing. The causes of drug toxicity can be classified in several ways and include mechanism-based (on-target) toxicity, immune hypersensitivity, off-target toxicity, and bioactivation/covalent modification. In addition, idiosyncratic responses are rare but can be one of the most problematic issues; several hypotheses for these have been advanced. Although covalent binding of drugs to proteins was described almost 40 years ago, the significance to toxicity has been difficult to establish; recent literature in this field is considered. The development of more useful biomarkers and short-term assays for rapid screening of drug toxicity early in the drug discovery/development process is a major goal, and some progress has been made using “omics” approaches.

References (81)

  • M.A. Tirmenstein et al.

    Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a non-hepatotoxic regioisomer, 3′-hydroxyacetanilide, in mouse liver

    J. Biol. Chem.

    (1989)
  • S. Bansal et al.

    Mitochondria-targeted cytochrome P450 2E1 preferentially induces oxidative damage and augments alcohol mediated mitochondrial dysfunction in cultured cells

    J. Biol. Chem.

    (2010)
  • U.A. Boelsterli et al.

    Mitochondrial abnormalities¯a link to idiosyncratic drug hepatotoxicity?

    Toxicol. Appl. Pharmacol.

    (2007)
  • Y.H. Lee et al.

    Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2 +/– mice: Two-stage oxidative injury

    Toxicol. Appl. Pharmacol.

    (2008)
  • T.P. Ryan et al.

    Strategic applications of toxicogenomics in early drug discovery

    Curr. Opin. Pharmacol.

    (2008)
  • D.E. Amacher

    The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity

    Toxicol. Appl. Pharmacol.

    (2010)
  • U.S. Food and Drug Administration: Challenge and opportunity on the critical path to new medical products

    (March 2004)
  • I. Kola et al.

    Can the pharmaceutical industry reduce attrition rates?

    Nat. Rev. Drug Discov.

    (2004)
  • J.F. Borzelleca

    Paracelsus: herald of modern toxicology

    Toxicol. Sci.

    (2000)
  • D.C. Liebler et al.

    Elucidating mechanisms of drug-induced toxicity

    Nat. Rev. Drug Discov.

    (2005)
  • B.K. Park et al.

    The role of metabolic activation in druginduced hepatotoxicity

    Annu. Rev. Pharmacol. Toxicol.

    (2005)
  • D.P. Zipes et al.

    Rosuvastatin: an independent analysis of risks and benefits

    MedGenMed

    (2006)
  • K. Landsteiner et al.

    Studies on the sensitization of animals with simple chemical compounds

    J. Exp. Med.

    (1935)
  • H.J. Zimmerman

    Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals in the Liver

    (1999)
  • E. Bjornsson

    Drug-induced liver injury: Hy's rule revisited

    Clin. Pharmacol. Ther.

    (2006)
  • J. Uetrecht

    Idiosyncratic drug reactions: current understanding

    Annu. Rev. Pharmacol. Toxicol.

    (2007)
  • J. Uetrecht

    Idiosyncratic drug reactions: past, present, and future

    Chem. Res. Toxicol.

    (2008)
  • J. Uetrecht

    Immune-mediated adverse drug reactions

    Chem. Res. Toxicol.

    (2009)
  • D.H. Adams et al.

    Mechanisms of immune-mediated liver injury

    Toxicol. Sci.

    (2010)
  • J.P. Uetrecht

    New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system

    Chem. Res. Toxicol.

    (1999)
  • I. Johansson et al.

    Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

    Proc. Natl. Acad. Sci. U.S.A.

    (1993)
  • M. Bourdi et al.

    A new anti-liver endoplasmic reticulum antibody directed against human cytochrome P-450 IA2: a specific marker of dihydralazine-induced hepatitis

    J. Clin. Invest.

    (1990)
  • P.M. Dansette et al.

    Drug-induced immunotoxicity

    Eur. J. Drug Metab. Pharmacokinet.

    (1998)
  • J.P. Luyendyk et al.

    Bacterial lipopolysaccharide exposure alters aflatoxin B1 hepatotoxicity: benchmark dose analysis for markers of liver injury

    Toxicol. Sci.

    (2002)
  • P. Matzinger

    The danger model: a renewed sense of self

    Science

    (2002)
  • P. Matzinger

    Friendly and dangerous signals: is the tissue in control?

    Nat. Immunol.

    (2007)
  • W.J. Pichler

    Delayed drug hypersensitivity reactions

    Ann. Intern. Med.

    (2003)
  • A. Kindmark et al.

    Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

    Pharmacogenet. J.

    (2008)
  • F.P. Guengerich et al.

    Applying mechanisms of chemical toxicity to predict drug safety

    Chem. Res. Toxicol.

    (2007)
  • D.J. Jollow et al.

    Acetaminophen-induced hepatic necrosis

    II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther.

    (1973)
  • Cited by (0)

    View full text